A cash-rich, post-tender biotech priced like a shell—despite a legally binding Takeda royalty/milestone engine and a high-upside KER-065 DMD/obesity option.
Overview
Keros Therapeutics (KROS) is a clinical-stage biotech focused on therapeutics that modulate the **TGF-β superfamily**, a set of master regulatory proteins influencing blood cell maturation and tissue growth/repair (muscle, bone, vasculature, cardiac tissue). The company’s pipeline and strategy materially changed in 2024–2025 after unexpected clinical outcomes. Most notably, Keros discontinued cibotercept (KER-012) for pulmonary arterial hypertension after halting/terminating Phase 2 TROPOS due to **pericardial effusion** adverse events, prompting a disciplined reprioritization. Today, value rests primarily on two assets: elritercept (KER-050) in hematology and KER-065 (rinvatercept) in neuromuscular/metabolic disease. Elritercept, targeting cytopenias in MDS/MF, was out-licensed globally (ex-China/HK/Macau) to **Takeda** effective Jan 2025, bringing a major non-dilutive capital infusion and future economic participation (milestones + royalties) while shifting late-stage cost and commercialization burden to the partner. Keros has pivoted internal focus and capital to KER-065, a myostatin/activin A inhibitor positioned for **Duchenne muscular dystrophy** and potentially obesity (as a lean-mass-preserving adjunct to GLP-1 therapy). With no marketed products, current revenue is collaboration-driven, led by the Takeda framework: **$200M upfront** recognized in 2025, a **$10M** milestone for Phase 3 RENEW first patient dosed, and transition services revenue, with up to **$1.11B** further milestones and tiered royalties if successful. The result is a company offering a rare mix of (a) de-risked partner economics and (b) proprietary early-stage upside, but still exposed to binary clinical execution and pathway safety risks.